Live News • Jul 09
Vor Biopharma Accelerates Telitacicept Trials for Autoimmune Diseases with $491.5 Million Reserve Vor Biopharma is shifting its core focus from oncology to late-stage autoimmune disease drug development, centering on telitacicept, a dual BAFF/APRIL inhibitor already approved in multiple indications in China and currently in Phase 3 trials for generalized myasthenia gravis and Sjögren’s disease, supported by a cash reserve of $491.5m.
The company’s pipeline and business priorities are now tied closely to telitacicept’s global clinical progress, with current studies targeting readouts into early 2029 and facing competition and regulatory hurdles in autoimmune indications such as gMG, Sjögren’s disease and IgA nephropathy.
Vor Biopharma’s stock trades at $19.75, with the share price up 69.7% year to date, reflecting a market that is already highly sensitive to updates on telitacicept and capital allocation decisions.
This pivot concentrates Vor Biopharma’s risk and potential reward in a single late-stage asset. As a result, trial outcomes, regulatory feedback and partnering terms are likely to have an outsized effect on shareholder value. Live News • Jul 08
Vor Biopharma Adds Biopharma Veteran Zaccardelli to Board as Phase 3 Milestone Nears Vor Biopharma has appointed David Zaccardelli, Pharm.D., to its Board of Directors, adding a biopharmaceutical leader with more than 20 years of experience in late-stage development, regulatory approval and commercial launches.
The company is advancing telitacicept, a therapy for autoimmune diseases, through global Phase 3 trials and views Zaccardelli’s track record with late-stage programs and commercialization as important support as it approaches potential regulatory and launch milestones.
Vor Biopharma’s stock trades at US$20.10, with a return of 72.7% year to date.
The key read-through is that Vor Biopharma is strengthening its governance and commercial experience ahead of potential telitacicept inflection points, which may help execution but also increases the importance of clinical and regulatory outcomes. Announcement • Jul 08
Vor Biopharma Announces Board Changes Vor Biopharma announced the appointment of David Zaccardelli, Pharm.D., to its Board of Directors. With more than 20 years of biopharmaceutical leadership experience, Dr. Zaccardelli has successfully built and led companies through late-stage development, regulatory approval, and commercial launch. Dr. Zaccardelli served as President, Chief Executive Officer, and on the board of directors of Verona Pharma from February 2020 until its acquisition by Merck for $10 billion in October 2025. During his tenure, Verona advanced from a clinical-stage company to a commercial-stage organization, successfully completing two Phase 3 trials, receiving FDA approval, and launching Ohtuvayre for chronic obstructive pulmonary disease. Under his leadership, Verona raised more than $1 billion to support development and commercialization and became one of the top-performing biotechnology companies on Nasdaq in 2024 based on its five-year increase in market value. Dr. Zaccardelli was recognized as Executive of the Year at the 2023 Scrip Awards. Currently, he serves as Chair of the Board of Directors for SAB BIO and Founder and Managing Member of Bull City Select Investments, LLC. Prior to Verona, Dr. Zaccardelli served as President and Chief Executive Officer of Dova Pharmaceuticals, a rare disease company acquired by Swedish Orphan Biovitrum in 2019 for up to $915 million. He previously served as Acting Chief Executive Officer of Cempra through its merger with Melinta Therapeutics and held several senior leadership roles at United Therapeutics Corporation, including Chief Operating Officer, Chief Manufacturing Officer and Executive Vice President, Pharmaceutical Development and Operations. Earlier in his career, Dr. Zaccardelli founded and led a contract research start-up and held clinical research roles at Burroughs Wellcome, Glaxo Wellcome and Bausch & Lomb Pharmaceutical. He received a Pharm.D. from the University of Michigan and completed a fellowship in clinical research and drug development at the University of North Carolina. In connection with Dr. Zaccardelli’s appointment, Andrew Levin, M.D., Ph.D., an Advisor at RA Capital Management, has stepped down from Vor Bio’s Board of Directors. 
